BR112012032235A2 - 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase - Google Patents

3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase

Info

Publication number
BR112012032235A2
BR112012032235A2 BR112012032235A BR112012032235A BR112012032235A2 BR 112012032235 A2 BR112012032235 A2 BR 112012032235A2 BR 112012032235 A BR112012032235 A BR 112012032235A BR 112012032235 A BR112012032235 A BR 112012032235A BR 112012032235 A2 BR112012032235 A2 BR 112012032235A2
Authority
BR
Brazil
Prior art keywords
chromene
pyrroles
dihydro
oxo
glycokinase activators
Prior art date
Application number
BR112012032235A
Other languages
English (en)
Portuguese (pt)
Inventor
Sarabu Ramakanth
Original Assignee
F Hoffmann La Roche Ag T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ag T filed Critical F Hoffmann La Roche Ag T
Publication of BR112012032235A2 publication Critical patent/BR112012032235A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012032235A 2010-06-17 2011-06-14 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase BR112012032235A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35561910P 2010-06-17 2010-06-17
PCT/EP2011/059783 WO2011157682A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Publications (1)

Publication Number Publication Date
BR112012032235A2 true BR112012032235A2 (pt) 2019-09-24

Family

ID=44266428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032235A BR112012032235A2 (pt) 2010-06-17 2011-06-14 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase

Country Status (10)

Country Link
US (1) US8178689B2 (https=)
EP (1) EP2582706A1 (https=)
JP (1) JP5844355B2 (https=)
KR (1) KR20130120993A (https=)
CN (1) CN102947311B (https=)
BR (1) BR112012032235A2 (https=)
CA (1) CA2801168A1 (https=)
MX (1) MX2012010668A (https=)
RU (1) RU2603191C2 (https=)
WO (1) WO2011157682A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6297590B2 (ja) * 2012-12-25 2018-03-20 ファ・メディシンＨｕａ Ｍｅｄｉｃｉｎｅ １−（［１，３］ジオキソラン−４−イルメチル）−１ｈ−ピラゾール−３−イルアミンを調製するための方法
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
US20210387996A1 (en) * 2018-10-24 2021-12-16 Hoffmann-La Roche Inc. Tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease
CN113493442B (zh) * 2020-04-03 2024-11-08 天津药物研究院有限公司 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138622A3 (en) 1983-10-18 1986-05-14 E.I. Du Pont De Nemours And Company 8-substituted pyrazolopentathiepins and related compounds
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
JPH0477477A (ja) 1990-07-18 1992-03-11 Takeda Chem Ind Ltd チアジアゾール酢酸誘導体の製造法
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL103678A (en) 1991-11-13 1996-09-12 Schering Ag History of pyrazolylpyrazole, processes for their preparation and herbicidal preparations containing them
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
DK1073672T3 (da) 1998-04-30 2003-12-08 Agouron Pharma Antipicornavirale forbindelser, deres fremstilling og anvendelse
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
ATE250053T1 (de) 1999-07-15 2003-10-15 Pharmacopeia Inc Bradikinin b1 rezeptor antagonisten
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1501815B1 (en) 2002-04-26 2006-11-22 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
WO2004033462A2 (en) 2002-10-09 2004-04-22 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1598349B1 (en) 2003-02-13 2011-07-27 Msd K.K. Novel 2-pyridinecarboxamide derivatives
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
EP1682524A1 (en) 2003-10-24 2006-07-26 Aventis Pharmaceuticals, Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
ATE517622T1 (de) 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
KR20070007104A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
WO2005090291A1 (en) 2004-03-16 2005-09-29 Wyeth Ion channel modulators
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CN101137631A (zh) 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
US7582769B2 (en) 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007053503A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
CA2637172A1 (en) 2006-01-27 2007-08-09 Array Biopharma Inc. Pyridin-2-amine derivatives and their use as glucokinase activators
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
CA2649577A1 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
MX2009009525A (es) 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators

Also Published As

Publication number Publication date
EP2582706A1 (en) 2013-04-24
US20110313002A1 (en) 2011-12-22
CA2801168A1 (en) 2011-12-22
CN102947311B (zh) 2015-11-25
US8178689B2 (en) 2012-05-15
MX2012010668A (es) 2012-10-03
CN102947311A (zh) 2013-02-27
RU2012156706A (ru) 2014-07-27
HK1178532A1 (zh) 2013-09-13
RU2603191C2 (ru) 2016-11-27
KR20130120993A (ko) 2013-11-05
WO2011157682A1 (en) 2011-12-22
JP5844355B2 (ja) 2016-01-13
JP2013532146A (ja) 2013-08-15

Similar Documents

Publication Publication Date Title
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BR112013000107A2 (pt) aminopirazoloquinazolinas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
BR112012029647A2 (pt) novos derivados de pirimidinas
UY33382A (es) Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
MX2011005934A (es) Compuestos organicos.
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
ECSP11011558A (es) Nuevos compuestos químicos.
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
BR112015011158A2 (pt) triazolopirazina
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
PH12016500092B1 (en) New azabenzimidazole derivatives
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
TW200738627A (en) Trialkylsilyl-indoles
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112012032235A2 (pt) 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase
BRPI0908569B8 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.